Chemotherapy of cervix cancer with mitolactol (dibromodulcitol, NSC 104800) and cisplatin: A Phase I study of the Gynecologic Oncology Group

G. A. Omura, J. L. Hubbard, Kenneth D Hatch, J. B. Schlaerth, J. A. Blessing

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

In this Phase I study, thirteen women with advanced cervix cancer were treated with mitolactol (dibromodulcitol) plus cisplatin to determine a maximum tolerable dose schedule. Response was not an objective of this study, but four partial responses were seen in nine patients with measurable lesions. In general, the therapy was well tolerated, but of the ten patients treated at the first dose level (cisplatin 50 mg/m2 intravenously on day 1 plus mitolactol 180 mg/m2 orally on days 2-6 every 3-4 weeks), 5 required deescalations and 8 required delays because of toxicity. All three patients treated with cisplatin plus a higher dose of mitolactol (270 mg/m2 x 5) required dose reductions and delays for hematologic toxicity. The first dose level appears tolerable by patients with, and promising in treating, advanced cervix cancer.

Original languageEnglish (US)
Pages (from-to)185-187
Number of pages3
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume15
Issue number3
StatePublished - 1992
Externally publishedYes

Fingerprint

Mitolactol
Uterine Cervical Neoplasms
Cisplatin
Drug Therapy
Appointments and Schedules

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Chemotherapy of cervix cancer with mitolactol (dibromodulcitol, NSC 104800) and cisplatin : A Phase I study of the Gynecologic Oncology Group. / Omura, G. A.; Hubbard, J. L.; Hatch, Kenneth D; Schlaerth, J. B.; Blessing, J. A.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 15, No. 3, 1992, p. 185-187.

Research output: Contribution to journalArticle

@article{81d921c5bb324bd5b933691b33422bcd,
title = "Chemotherapy of cervix cancer with mitolactol (dibromodulcitol, NSC 104800) and cisplatin: A Phase I study of the Gynecologic Oncology Group",
abstract = "In this Phase I study, thirteen women with advanced cervix cancer were treated with mitolactol (dibromodulcitol) plus cisplatin to determine a maximum tolerable dose schedule. Response was not an objective of this study, but four partial responses were seen in nine patients with measurable lesions. In general, the therapy was well tolerated, but of the ten patients treated at the first dose level (cisplatin 50 mg/m2 intravenously on day 1 plus mitolactol 180 mg/m2 orally on days 2-6 every 3-4 weeks), 5 required deescalations and 8 required delays because of toxicity. All three patients treated with cisplatin plus a higher dose of mitolactol (270 mg/m2 x 5) required dose reductions and delays for hematologic toxicity. The first dose level appears tolerable by patients with, and promising in treating, advanced cervix cancer.",
author = "Omura, {G. A.} and Hubbard, {J. L.} and Hatch, {Kenneth D} and Schlaerth, {J. B.} and Blessing, {J. A.}",
year = "1992",
language = "English (US)",
volume = "15",
pages = "185--187",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Chemotherapy of cervix cancer with mitolactol (dibromodulcitol, NSC 104800) and cisplatin

T2 - A Phase I study of the Gynecologic Oncology Group

AU - Omura, G. A.

AU - Hubbard, J. L.

AU - Hatch, Kenneth D

AU - Schlaerth, J. B.

AU - Blessing, J. A.

PY - 1992

Y1 - 1992

N2 - In this Phase I study, thirteen women with advanced cervix cancer were treated with mitolactol (dibromodulcitol) plus cisplatin to determine a maximum tolerable dose schedule. Response was not an objective of this study, but four partial responses were seen in nine patients with measurable lesions. In general, the therapy was well tolerated, but of the ten patients treated at the first dose level (cisplatin 50 mg/m2 intravenously on day 1 plus mitolactol 180 mg/m2 orally on days 2-6 every 3-4 weeks), 5 required deescalations and 8 required delays because of toxicity. All three patients treated with cisplatin plus a higher dose of mitolactol (270 mg/m2 x 5) required dose reductions and delays for hematologic toxicity. The first dose level appears tolerable by patients with, and promising in treating, advanced cervix cancer.

AB - In this Phase I study, thirteen women with advanced cervix cancer were treated with mitolactol (dibromodulcitol) plus cisplatin to determine a maximum tolerable dose schedule. Response was not an objective of this study, but four partial responses were seen in nine patients with measurable lesions. In general, the therapy was well tolerated, but of the ten patients treated at the first dose level (cisplatin 50 mg/m2 intravenously on day 1 plus mitolactol 180 mg/m2 orally on days 2-6 every 3-4 weeks), 5 required deescalations and 8 required delays because of toxicity. All three patients treated with cisplatin plus a higher dose of mitolactol (270 mg/m2 x 5) required dose reductions and delays for hematologic toxicity. The first dose level appears tolerable by patients with, and promising in treating, advanced cervix cancer.

UR - http://www.scopus.com/inward/record.url?scp=0026719103&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026719103&partnerID=8YFLogxK

M3 - Article

C2 - 1590269

AN - SCOPUS:0026719103

VL - 15

SP - 185

EP - 187

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 3

ER -